NASDAQ:ALLKAllakos Stock Price, Forecast & News

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALLK stock has increased by 28.8% and is now trading at $75.07.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Allakos.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020.
View our earnings forecast for Allakos.

Allakos Inc (NASDAQ:ALLK) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.57) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.01.
View Allakos' earnings history.

3 Wall Street analysts have issued twelve-month target prices for Allakos' shares. Their forecasts range from $36.00 to $94.00. On average, they expect Allakos' stock price to reach $65.00 in the next year. This suggests that the stock has a possible downside of 13.4%.
View analysts' price targets for Allakos.

Headlines about ALLK stock have trended negative on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allakos earned a news impact score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Allakos.

Some companies that are related to Allakos include Catalent (CTLT), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Bausch Health Companies (BHC) and ACADIA Pharmaceuticals (ACAD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Ascendis Pharma A/S (ASND) and Autolus Therapeutics (AUTL).

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by a variety of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.23%), SG Americas Securities LLC (0.04%), Mackay Shields LLC (0.04%), Dupont Capital Management Corp (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.00%) and UBS Group AG (0.00%). Company insiders that own Allakos stock include Guy P Nohra, John P Mckearn and Venture Fund (Ohi Rivervest II.
View institutional ownership trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Allakos company stock in the last year include Guy P Nohra, and John P Mckearn.
View insider buying and selling activity for Allakos.

ALLK stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., SG Americas Securities LLC, Dupont Capital Management Corp, Mackay Shields LLC, UBS Group AG, Zurcher Kantonalbank Zurich Cantonalbank , and Strs Ohio.
View insider buying and selling activity for Allakos.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $75.07.

Allakos has a market capitalization of $3.66 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]